|
|
|||
| |||||||||||||||||||||||||||||||||||||
Clinical testing for BRCA mutations became available in 1996 as a means for the identification of women with a high lifetime risk of breast and ovarian cancer. This innovation was widely viewed as a medical breakthrough. Shobita Parthasarathy's intriguing but ultimately unconvincing book compares the introduction of BRCA testing in the United States and in the United Kingdom. In considering two societies with different health care systems but with much else in common, she seeks to determine how national context shapes the understanding and practice of genetic medicine.
At the heart of Parthasarathy's comparison is the rise of Myriad Genetics,
HOME | SUBSCRIBE | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | PRIVACY | HELP | beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved. |